Fwd: IACM-Bulletin of 18 July 2010

Skip to first unread message

David Knowles

Oct 5, 2010, 11:54:27 AM10/5/10
to virgin-islands-m...@googlegroups.com

---------- Forwarded message ----------
From: <in...@cannabis-med.org>
Date: Sun, Jul 18, 2010 at 7:30 AM
Subject: IACM-Bulletin of 18 July 2010
To: e...@cannabis-med.org

IACM-Bulletin of 18 July 2010

In the last IACM-Bulletin there were two mistakes on prices of
medical cannabis products. These concern the price of THC per
mg in Sativex, which was reported higher than it is, and the price
of THC per mg in a cannabis extract of THC Pharm, which was
reported lower than it is. The paragraph has to read as follows:
"Each vial of 10 ml of Sativex contains approximately 90 sprays,
which means that a vial contains about 243 mg THC. One
milligram of THC would cost about 0.62 Euros (about 0.76 US
Dollars). The price of Marinol (THC) in the USA depends on
package size and is about 2.20 US Dollars per mg (1.80 Euros).
The price of THC (dronabinol) in Germany is about 0.80 Euros
per mg. The price of 1 gram of cannabis extract of the German
company THC Pharm with 630 mg THC, made available to
patients with an exemption to use cannabis in Germany is 225
Euros, making 1 mg costing 0.36 Euros. The price of  THC in
the cannabis variety Bedrocan (19 per cent THC, 9 Euros per
gram) sold in Dutch pharmacies is about 0.05 Euros/mg."

* Science/USA: Legalization of cannabis in California would
significantly reduce the price and increase use according to a


Science/USA: Legalization of cannabis in California would
significantly reduce the price and increase use according to a

Legalizing cannabis in California could reduce prices of the drug
while its use could double, research group RAND Corporation
reported on 7 July. Voters in the most populous state of the
USA will decide in a November referendum on whether to
make the use and cultivation of cannabis legal. Even if it is
approved, cannabis would remain illegal under federal law and it
is unclear how national authorities might respond. Under the
state initiative, local authorities would decide whether to allow
sales and cultivation, but all adults would be allowed to use
cannabis under state law. A separate state bill would legalize
cannabis and tax it at a rate of 50 US Dollars (about 39 Euros)
an ounce (28.5 grams), a move a state tax board calculated
would raise 1.4 billion dollars.

The RAND study calculated that the untaxed price of high
quality cannabis could fall to as low as 38 dollars plus 50 dollars
of taxes resulting in 88 dollars (about 70 Euros) per ounce from
around 375 dollars (about 290 Euros) per ounce today. "Even
under a scenario with high taxes ($50 per ounce) and a
moderate rate of tax evasion (25 percent), researchers cannot
rule out consumption increases of 50 percent to 100 percent,
and possibly even larger," RAND said in a statement. However
such estimates were imprecise because legalization would be
such an unprecedented move, researchers said. California could
become a big exporter of cannabis and imports from Mexico
would dramatically drop.

More at:
- http://www.reuters.com/article/idUSTRE6664IV20100707

(Sources: Reuters of 7 July 2010, Associated Press of 7 July


News in brief

***Israel: Cannabinoid conference
To honour Dr. Raphael Mechoulam a conference on
"Cannabinoids in Biology and Medicine" will be organized by the
Institute for Advanced Studies of the Hebrew University of
Jerusalem in conjunction with the Israel Science Foundation on
31 October to 4 November 2010. Prof. Mechoulam will
celebrate his 80th birthday on 5 November 2010. For
information on the conference please visit:

***USA: Oregon
Obtaining an Oregon medical-cannabis card no longer will be
limited to Oregon residents. As part of a review of otherwise
routine changes proposed in the rules, the Department of Justice
has advised the Department of Human Services that the 1998
law authorizing medical cannabis is not limited to residents of the
state. As of 1 July 2010, there were 36,380 card holders. More
at: http://oregon.gov/DHS/ph/ommp/data.shtml (Source:
Statesman Journal of 10 July 2010)

***USA: Montana
A Montana group is shutting down its travelling medical cannabis
clinics following criticism that the so-called cannabis caravans
have added thousands of people to the state registry without
conducting thorough patient screenings. The Montana
Caregivers Network has hosted the one-day clinics in hotels and
conference centres across Montana for more than a year. For a
fee of 150 US Dollars (about 116 Euros), the group brought
together those seeking to become medical cannabis patients with
doctors willing to prescribe the drug. (Source: Associated Press
of 10 July 2010)

***Science: Cognition
According to research at the Columbia University, USA, the
acute use of cannabis by regular cannabis users did not
significantly alter overall performance accuracy in computerized
cognitive tasks. 24 volunteers who reported smoking about 24
cannabis cigarettes per week participated in tests where they
received either placebo or cannabis cigarettes. (Source: Hart
CL, et al. Pharmacol Biochem Behav. 2010 Jun 18. [in press])

***Science: Personalized medicine
In an editorial Dr. Onaivi from William Paterson University in
Wayne, USA, suggests that it may be possible to identify
patients who respond to a therapy with cannabinoids or other
substances that modulate the endocannabinoid system by
examining genetic variables and mutations of the
endocannabinoid system. (Source: Onaivi ES.
Pharmacogenomics 2010;11(7):907-10.)

***Science: Cannabichromene
Researchers of the Virginia Commonwealth University in
Richmond, USA, investigated the pharmacology of the natural
plant cannabinoid cannabichromene (CBC). CBC was active in
the tetrad test, which consists of the following four endpoints:
hypomotility, antinociception, catalepsy, and hypothermia. This
effect was increased by a low dose of THC. In addition, CBC
elicited anti-inflammatory effects.  CBC effects were not
mediated by CB1 or CB2 receptors. (Source: Delong GT, et al.
Drug Alcohol Depend. 2010 Jul 8. [in press])

***Science: Fatty acids
According to research at the Wageningen University, The
Netherlands, highly unsaturated fatty acids in fish oil are partly
converted into ethanolamines in the body. These ethanolamines
possess anti-inflammatory properties, which may contribute to
the beneficial health effects of these fatty acids. They may bind
to cannabinoid receptors. Authors suggest that "different targets,
including the endocannabinoid system, may be involved in the
immune-modulating activity" of these fish-oil-derived
ethanolamines. (Source: Balvers MG, et al. Biochim Biophys
Acta. 2010 Jul 2. [in press])

***Science: Fibrosis
According to animal research at the University of Erlangen-
Nuremberg, Germany, activation of the CB1 receptor increased
the negative consequences in bleomycin-induced dermal fibrosis,
while mice without CB1 receptors were protected from these
consequences. Authors concluded that "inactivation of CB1
exerts potent anti-fibrotic effects in inflammation-driven models
of fibrosis." (Source: Marquart S, et al. Arthritis Rheum. 2010
Jul 8. [in press])

***Science: Pregnancy
Exposition to cannabis before birth may be associated with
deficits in later life. Researchers of the University of Pittsburgh,
USA, followed children with prenatal exposure to different drugs
until the age of 16. As was the case for prenatal tobacco
exposure, cannabis exposure was also associated with deficits in
visual-motor coordination. (Source: Willford JA, et al.
Neurotoxicol Teratol. 2010 Jun 30. [in press])

***Science: Liver injury
Researchers at the INSERM, France, investigated the impact of
CB2 receptors on the regenerative process associated with liver
injury following acute hepatitis induced by a chemical in mice.
Treatment with a synthetic CB2 receptor agonist (JWH-133)
reduced liver injury and accelerated liver regeneration. (Source:
Teixeira-Clerc F, et al. Hepatology 2010 May 25. [in press]

* Crowther SM, Reynolds LA, Tansey EM, eds. The
Medicalization of Cannabis. Wt Centre for the History of
Medicine at UCL. ISBN: 978-0854841295.

International Association for Cannabinoid Medicines (IACM)
Am Mildenweg 6
D-59602 Ruethen
Phone: +49 (0)2952-9708571
Fax: +49 (0)2952-902651
Email: in...@cannabis-med.org

If you want to be deleted from or added to the IACM-Bulletin
mailing list or if you want to change your e-mail address please
www.cannabis-med.org/english/subscribe.htm. You may choose
between different languages (English, German, French, Dutch,
Italian and Spanish).

The articles of the IACM-Bulletin can be printed, translated and
distributed freely for any non-commercial purposes, provided
the original work is properly cited. The source of the IACM-
Bulletin is "IACM, www.cannabis-med.org".

David Knowles

Safe Access to Medical cannabis in the US Virgin Islands
Decriminalize possession for
responsible adults
Agricultural Hemp

Reply all
Reply to author
0 new messages